started · updated
Sandoz and Henlius Biotech sign $322 million biosimilar deal
Sandoz has entered into a strategic collaboration with Shanghai Henlius Biotech to develop and commercialize up to ten biosimilar products. Under the terms of the agreement, Sandoz will receive exclusive commercialization rights for these products outside of China, while Henlius will manage development, manufacturing, and supply.
The initial phase of the deal focuses on three specific biosimilars: a candidate for treating colorectal cancer (cetuximab), a treatment for hypercholesterolemia (evolocumab), and a treatment for lupus (belimumab). The agreement includes an option for an additional asset, such as recombinant human hyaluronidase.
The total value of the collaboration could reach $322 million, including upfront payments, development milestones, and commercial milestones. Sandoz is expected to pay up to $77 million upfront, with near-term payments potentially reaching $100.5 million in the current fiscal year. This partnership is part of Sandoz’s strategy to expand its biosimilar pipeline and capitalize on the global market for medicines facing loss of exclusivity.
Entities
Amgen · Bristol-Myers Squibb · GSK · Sandoz · Shanghai Henlius Biotech
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 6 SOURCES] Sandoz will gain global commercialization rights for the three drugs outside of China. mix929.com · wdez.com · kelo.com · wxerfm.com · kfgo.com · +1 more
- [● 6 SOURCES] The three biosimilar drugs treat cholesterol, lupus, and colorectal cancer. mix929.com · wdez.com · kelo.com · wxerfm.com · kfgo.com · +1 more
- [○ 1 SOURCE] The total value of the cooperation agreement can reach up to $322 million. www.bondguide.de
- [○ 1 SOURCE] The agreement expands Sandoz's pipeline to 39 assets, with the potential to reach 46 assets. www.bondguide.de
- [● 6 SOURCES] Henlius is eligible for development milestone payments up to $160 million and commercial milestone payments up to $77 million. mix929.com · wdez.com · kelo.com · wxerfm.com · kfgo.com · +1 more
- [● 6 SOURCES] Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs. mix929.com · wdez.com · kelo.com · wxerfm.com · kfgo.com · +1 more